Symptomatic treatment of neurologic symptoms in Wilson disease
Language English Country Netherlands Media print
Document type Journal Article, Review
PubMed
28433105
DOI
10.1016/b978-0-444-63625-6.00018-5
PII: B978-0-444-63625-6.00018-5
Knihovny.cz E-resources
- Keywords
- Wilson disease, botulinum toxin, deep-brain stimulation, dopamine, dystonia, parkinsonism, tremor,
- MeSH
- Chelating Agents therapeutic use MeSH
- Dystonic Disorders therapy MeSH
- Dystonia therapy MeSH
- Hepatolenticular Degeneration complications therapy MeSH
- Humans MeSH
- Nervous System Diseases therapy MeSH
- Tremor therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Chelating Agents MeSH
Wilson disease (WD) is a potentially treatable neurodegenerative disorder. In the majority of cases, treatment with drugs that induce a negative copper balance (usually chelators or zinc salts) leads to improvements in liver function and neurologic signs. However, some patients show severe neurologic symptoms at diagnosis, such as tremor, dystonia, parkinsonism, and chorea. In this patient group, some neurologic deficits may persist despite adequate treatment, and further neurologic deterioration may be observed after treatment initiation. Such patients may require additional treatment to alleviate neurologic symptoms. Apart from general recommendations for WD anticopper treatment, there are currently no guidelines for managing neurologic symptoms in WD. The aim of this chapter is to summarize possible treatments of neurologic symptoms in WD based on the presently available medical literature.
References provided by Crossref.org
Neurologic impairment in Wilson disease